Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
20
2
2020
medline:
4
9
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
The aim of this review is to highlight the conceptual and practical knowledge for interpreting score changes in patient-reported outcomes (PROs) that have been validated for chronic spontaneous urticaria (CSU). The urticaria guidelines recommends to assess PROs as Health-Related Quality of Life, disease activity and disease control, to detect the CSU impact and the overall treatment effect. To this aim it is crucial to determine the minimal important difference (MID) to assess if changes in questionnaire scores represent either perceived improvement or deterioration for patients. Methods for establishing the MID are well defined and are clustered into two broad categories: distribution-based and anchor-based. For the majority of the available questionnaires for CSU, an MID has been defined, according to the results of various approaches. In most of the studies in our review, anchor-based methods, either alone or in combination with distribution ones, were used. The available information regarding MIDs across validated tools for CSU patients helps to interpret measurement scores and allows the implementation of PROs in routine practices.
Identifiants
pubmed: 32073436
doi: 10.1097/ACI.0000000000000636
pii: 00130832-202006000-00008
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
261-267Commentaires et corrections
Type : ErratumIn
Références
Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14:214–220.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 2018; 73:1393–1414.
Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H-antihistamine resistant chronic spontaneous urticaria patients: results from X-ACT, a randomised controlled trial. Allergy 2016; 71:1135–1144.
Sussman G, Abuzakouk M, Bérard F, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy 2018; 73:1724–1734.
Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil's itch. J Allergy Clin Immunol Pract 2018; 6:1097–1106.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270–1277.
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66:317–330.
Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016; 175:1153–1165.
O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197–201.
Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor–patient relation. Allergy 2009; 64:581–588.
Balp MM, Khalil S, Tian H, et al. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol 2018; 32:282–290.
Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017; 47:684–692.
Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58:621–623.
O’Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am 2014; 34:89–104.
Weller K, Zuberbier T, Maurer M. Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr Opin Allergy Clin Immunol 2015; 15:220–226.
Weller K, Siebenhaar F, Hawro T, et al. Clinical measures of chronic urticaria. Immunol Allergy Clin North Am 2017; 37:35–49.
Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol 2017; 56:1342–1348.
Patrick DL, Burke LB, Powers JH, et al. Patient reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10:S125–S137.
US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research and US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient reported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes 2006; 4:79.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HROL) measures in the evaluation of medicinal products. 2005; London: European Medicines Agency website, Available at: http://www.emea.euro [Cited April 2007].
Guyatt GH, Oxman AD, Vist G, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–926.
Finlay A, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine in clinical use. Clin Exp Dermatol 1994; 19:210–216.
Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin diseases: reliability, validity and responsiveness. J Invest Dermatol 1996; 107:707–713.
Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60:1073–1078.
Baiardini I, Braido F, Molinengo G, et al. Chronic urticaria patient perspective (CUPP): the first validated tool for assessing quality of life in clinical practice. J Allergy Clin Immunol Pract 2018; 6:208–218.
Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012; 67:1289–1298.
Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63:777–780.
Jariwala SP, Moday H, de Asis ML, et al. The urticaria severity score: a sensitive questionnaire/index for monitoring response to therapy in patients with chronic urticaria. Ann Allergy Asthma Immunol 2009; 102:475–482.
Maurer M, Mathias SD, Crosby RD, et al. Validity and responsiveness of the urticaria activity and impact measure: a new patient-reported tool. Ann Allergy Asthma Immunol 2018; 120:641–647.
Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score. Allergy 2013; 68:1185–1192.
Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133:1365–1372.
Weller K, Donoso T, Magerl M, et al. Development of the angioedema control test (AECT) – a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 2019; [Epub ahead of print].
Baiardini I, Braido F, Bindslev-Jensen C, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy 2011; 66:840–844.
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59:12–19.
Johnston BC, Ebrahim S, Carrasco-Labra A, et al. Minimally important difference estimates and methods: a protocol. BMJ Open 2015; 5:e007953.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407–415.
Schünemann HJ, Puhan M, Goldstein R, et al. Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ). COPD 2005; 2:81–89.
Schünemann HJ, Guyatt GH. Commentary–goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res 2005; 40:593–597.
Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2:221–226.
Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56:395–407.
Ward MM, Marx AS, Barry NN. Identification of clinically important changes in health status using receiver operating characteristic curves. J Clin Epidemiol 2000; 53:279–284.
Turner D, Schünemann HJ, Griffith LE, et al. Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference. J Clin Epidemiol 2009; 62:374–379.
Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61:102–109.
Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-min walk test distance of adults with pathology: a systematic review. J Eval Clin Pract 2017; 23:377–381.
Ferreira PL, Gonçalo M, Ferreira JA, et al. Psychometric properties of the Portuguese version of the chronic urticaria quality of life questionnaire (CU-Q2oL). Health Qual Life Outcomes 2019; 17:190.
Salman A, Demir G, Bekiroglu N. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: real-life data. Dermatol Ther 2019; 32:e12975.
Shikiar R, Harding G, Leahy M, et al. Minimal important difference (MID) of the dermatology life quality index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005; 3:36.
Kessel A, Graif Y, Vadasz Z, et al. Adaptation and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL). Isr Med Assoc J 2016; 18:461–465.
Baiardini I, Fasola S, Maurer M, et al. Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2019; 74:2542–2544.
MOXIE. https://moxie-gmbh.de/medical-products. [https://moxie-gmbh.de/medical-products]. Available at: http://moxie-gmbh.de/medical-products/. Accessed January 30, 2020.
Weller K, Magerl M, Peveling-Oberhag A, et al. The Angioedema Quality of Life Questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy 2016; 71:1203–1209.
Kulthanan K, Chularojanamontri L, Rujitharanawong C, et al. Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change. Health Qual Life Outcomes 2019; 17:160.
Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract 2018; 6:1185–1190.
Ohanyan T, Schoepke N, Bolukbasi B, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol 2017; 140:1710–1713.